Location of Repository

Dose selection in seamless phase II/III clinical trials based on efficacy and toxicity

By Peter K. Kimani

Abstract

Seamless phase II/III clinical trials are attractive in development of new drugs because they accelerate the drug development process. Seamless phase II/III trials are carried out in two stages. After stage 1 (phase II stage), an interim analysis is performed and a decision is made on whether to proceed to stage 2 (phase III stage). If the decision is to continue with further testing, some dose selection procedure is used to determine the set of doses to be tested in stage 2. Methodology exists for the analysis of such trials that allows complete flexibility of the choice of doses that continue to the second stage. There is very little work, however, on optimizing the selection of the doses. This is a challenging problem as it requires incorporation of the dose-response relationship, of the observed safety profile and of the planned analysis method. In this thesis we propose a dose-selection procedure for binary outcomes in adaptive seamless phase II/III clinical trials that incorporates the dose response relationship, and explicitly incorporates both efficacy and toxicity. The choice of the doses to continue to stage 2 is made by comparing the predictive power of the potential sets of doses which might continue to stage 2

Topics: R1
OAI identifier: oai:wrap.warwick.ac.uk:2765

Suggested articles

Preview

Citations

  1. (2006). Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios. doi
  2. (1975). Bayesian inference for bioassay.
  3. (2000). Closed multiple testing procedures and proc multtest.
  4. (1999). Decision theoretic designs for phase II clinical trials with multipe outcomes. doi
  5. (1989). Designand analysisof phaseI clinicaltrials.
  6. (2006). Phase II/III seamless adaptive designs with Bayesian decision tools for an efficient development of a targeted therapy in oncology. doi
  7. (1994). Practical Bayesian guidelines for phase IIB clinical trials. doi
  8. (1993). Resampling-Based Multiple Testing: Examples and Methods for p-value Adjustment. doi
  9. (2003). Sequential designs for phase III clinical trials incorporating treatment selection. doi
  10. (1997). The Design and Analysis of Sequential Clinical doi
  11. (2002). Truncated product method for combining p-values. doi
  12. (1988). Two-stage selection and testing designs for comparative clinical trials. doi
  13. (2006). Using Bayesian Decision Theory in Dose-escalation studies, Statistical Methods for Dose-Finding Experiments. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.